stockportfolio.pro
Stocks / AZN vs MRK
AZN vs MRK
AstraZeneca PLC and Merck & Co., Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| AstraZeneca PLC (AZN) | Merck & Co., Inc. (MRK) | |
|---|---|---|
| Market cap | $281.1B | $295.4B |
| Revenue (latest FY) | $58.74B | $65.01B |
| Net income (latest FY) | $10.22B | $18.25B |
| Revenue growth (5y CAGR) | 9.8% | 9.4% |
| Net margin | 17.4% | 28.1% |
| Return on equity | 21.0% | 34.7% |
| P/E ratio | 27.3 | 33.7 |
| Dividend yield | 1.8% | 2.8% |
| Profitable years (of last 10) | 4 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AZN — free Open MRK — freeFrequently asked questions
Which is bigger, AZN or MRK?
Merck & Co., Inc. is larger by market capitalization — $295.4B versus $281.1B.
Which grows faster, AZN or MRK?
Over the last five fiscal years, AstraZeneca PLC grew revenue faster — 9.8%/yr versus 9.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.